Best of ASCO - 2014 Annual Meeting

 

Welcome

Uterine Cancer

Gynecologic Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A 12 multigene NGS panel to characterize molecular biotypes in endometrial cancer.

Ignacio Romero

5591

Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.

Martee Leigh Hensley

5505

Adjuvant radiation “sandwiched” between 6 cycles of carboplatin and paclitaxel for FIGO stage III endometrioid adenocarcinoma.

Nicola Joseph Nasser

e17567

Adjuvant therapy may decrease disparities in outcomes for black endometrial cancer patients.

Fan Zhu

5587

Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: A Gynecologic Oncology Group/NRG study.

Ursula A. Matulonis

5589

Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.

Stephanie Gaillard

5590

Association of thrombocytosis with disease specific survival in women with uterine papillary serous carcinoma.

Margot Gardin

e17561

Differences in survival outcomes in advanced endometrial cancer due to variation in adjuvant therapy and histology.

Emily Meichun Ko

5588

DNA methylation-based classifier for diagnosis of endometrial cancer.

Shengyang Wu

e17570

Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.

Kosei Hasegawa

5594

Experience of gynecologic oncologists regarding endometrial cancer after endometrial ablation.

Hui Chen

e17566

Genomic profiling of lymph node metastases in endometrial cancer and association with volume of metastasis.

Stephanie Sullivan

5586

Grade and maximum tumor dimension (MTD) as determinants of lymphadenectomy in patients with endometrioid endometrial cancer (EEC).

Ali Ahmad Bazzi

e17560

Immune checkpoint inhibitor (anti PD-1/PD-L1 antibody activity in dedifferentiated endometrial carcinoma.

Ruriko Ono

e17565

Patterns of care and survival outcomes of stage IIIA endometrial cancer: An analysis of the National Cancer Database.

Sherry Yan

5592

Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.

Shannon Neville Westin

5504

Prognosis and survival of stage I endometrial stromal sarcoma (ESS) and uterine adenosarcoma: Analysis of the National Cancer Database (NCDB).

Devalkumar Rajyaguru

e17569

Quality of life (QoL) in a phase III trial of pelvic external beam radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk, early stage endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group study.

Vivian Vongruenigen

5593

Roles of an immune-check point inhibitor (nivolumab) in heavily pretreated and platinum-resistant gynecologic cancers.

Yoshihiro Kikuchi

e17562

STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.

Tim Mould

TPS5615

Venous thromboembolism is associated with advanced cancer stage, hypertension and cardiovascular disease regardless of latency from surgery in patients with uterine serous carcinoma.

Gregory M. Gressel

e17568

ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).

David S. Miller

5503